Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Phathom Pharmaceuticals, Inc.

NASDAQ: PHAT · Life Sciences · 5 alerts · CIK 1783183

Share price
$5.88Close, Nov 16
Market cap
$478M
Shares outstanding
81.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Phathom Pharmaceuticals, Inc. filings on SEC EDGAR ↗

7:06 AM ET 10-Q
Financial Results

Phathom Pharmaceuticals Q3 2026 Results: Net Loss of $13.9M, Loss Narrows

Phathom Pharmaceuticals reported a significant increase in net product revenue to $84.7 million for Q3 2026, up from $49.5 million in the prior year. The company substantially narrowed its quarterly net loss to $13.9 million compared to $30.0 million in Q3 2025, driven by higher gross profits and reduced operating expenses.

Key figure
Net loss $13.9M
7:05 AM ET 8-K
Financial Results

Phathom Pharmaceuticals Financial Results

Phathom Pharmaceuticals reported Q3 2026 net revenues of $84.7 million, a 71% increase year-over-year, driven by the commercial momentum of VOQUEZNA which surpassed 2 million total prescriptions filled. The company achieved positive operating cash flow for the second consecutive quarter and initiated a Phase 3 study for as-needed use of VOQUEZNA in NERD patients.

Term
Q3 2026

“We are pleased to report continued solid revenue growth and improved operating profitability for the third quarter. We continue to grow VOQUEZNA prescribing depth among GI providers and have implemented several initiatives designed to make it easier for physicians to prescribe and patients to obtain our first-in-class GERD treatment. These efforts build on our commercial momentum, which includes recently reaching the milestone of two million VOQUEZNA prescriptions filled.”

Steve Basta, President and Chief Executive Officer of Phathom

“Our third quarter results reflect Phathom’s significant financial transformation, with revenue growth of 71% year over year and positive cash flow from operations for the second consecutive quarter. We have established a stronger financial foundation through continued revenue growth and disciplined expense management, while maintaining the flexibility to invest in our commercial and clinical development priorities. We remain confident in our ability to meet our financial obligations and deliver on our full-year 2026 guidance.”

Sanjeev Narula, Chief Financial and Business Officer of Phathom

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.